Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Signaling in leukemia: which messenger to kill?
Warren S. Pear
Warren S. Pear
Published February 15, 2000
Citation Information: J Clin Invest. 2000;105(4):419-422. https://doi.org/10.1172/JCI9461.
View: Text | PDF
Commentary

Signaling in leukemia: which messenger to kill?

  • Text
  • PDF
Abstract

Authors

Warren S. Pear

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
TEL/PDGFβR leukemogenesis is influenced by phosphotyrosine interactions....
TEL/PDGFβR leukemogenesis is influenced by phosphotyrosine interactions. At the left is 1 chain of PDGFβR, showing tyrosine residues that become phosphorylated after ligand binding. The signaling complex is a dimer (only 1 chain is shown). Strongly interacting proteins are shown adjacent to the tyrosine residues to which they bind. As shown by STAT and PI3K, proteins can interact with multiple tyrosines. The right panels show TEL/PDGFβR and the mutant proteins analyzed by Tomasson et al. (2). Only tyrosine residues that were mutated in their work are shown. The phenotypes of mice receiving the wild-type and mutant constructs are listed below each construct. “ΔPNT” indicates deletion removing the pointed domain (indicated by the shaded box in TEL), which is necessary for oligomerization.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts